コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 orpholinone and the piperidinone series will be described herein.
2 eir activity in in vitro and in vivo models, is described herein.
3 ontaining polycyclic conjugated hydrocarbons is described herein.
4 oronic acids, and N-fluorobenzenesulfonimide is described herein.
5 egy of delivering hydrogen persulfide (H2S2) is described herein.
6 ylates to unusual chiral cyclic sulfoximines is described herein.
7 a-nitrogenated aldehydes in very good yields is described herein.
8 mma-keto allyl phosphonates in 70-93% yields is described herein.
9 of phosphorothioate and native DNA sequences is described herein.
10 e, mild bromination of thieno[2,3-b]pyridine is described herein.
11 epoxide-based cation-pai bicyclizations that is described herein.
12 titanocene-catalyzed multicomponent coupling is described herein.
13 A novel PCR assay is described herein.
14 tal characterization of a DC-only ion funnel is described herein.
15 opy of a Neisseria gonorrhoeae 16S rRNA gene is described herein.
16 azinanones, precursors to verdazyl radicals, is described herein.
17 relatively nonstabilized carbon nucleophiles is described herein.
18 kaloid and potential biosynthetic precursor, is described herein.
19 ally hindered proazaphosphatrane shown above is described herein.
20 pha-chloro and alpha-fluoro carboxylic acids is described herein.
21 e self-assembly and subsequent hydrogelation is described herein.
22 of a class of indole cPLA 2 alpha inhibitors is described herein.
23 An X-ray crystal structure of this complex is described herein.
24 determined to actually have a chylous cyst, is described herein.
25 (MBE) on c-plane sapphire and GaN templates is described herein.
26 The SAR study leading to the discovery of 6b is described herein.
27 accharides to polypeptides and even proteins is described herein.
28 okinetic profile of this series of compounds is described herein.
29 mide) dendrimers up to the second generation is described herein.
30 ent four-step synthetic route for compound 1 is described herein.
31 y of different imaging or therapeutic agents is described herein.
32 ed tetracyclic core of phomoidrides B and D, is described herein.
33 synthesis of several quinone sesquiterpenes is described herein.
34 the scope and limitations of such reactions is described herein.
35 ytic asymmetric alpha-amination of aldehydes is described herein.
36 netically engineered enzyme-ligand conjugate is described herein.
37 2, utilizing a palladium-catalyzed coupling, is described herein.
38 Lewis acid ionophore [9]mercuracarborand-3, is described herein.
39 hen]-3(2H)-one (DEMAX) for Al(III) chelation is described herein.
40 pired synthesis of Pinoxaden metabolites 2-5 is described herein.
41 presence of I(2)/DMSO with 2-aminobenzamide is described herein.
42 ss-coupling of thioacetates and aryl halides is described herein.
43 3))-H bonds aided by native directing groups is described herein.
44 cular iron-catalyzed oxyamination of alkenes is described herein.
45 tic and aliphatic thiols at room temperature is described herein.
46 a-thioacetic acids to form biaryl thioethers is described herein.
47 ctive pyridazinone, the development of which is described herein.
48 ently under phase II clinical investigation, are described herein.
49 nazoline and quinoline-based AAK1 inhibitors are described herein.
50 e eastern Pacific Ocean targeted for mining, are described herein.
51 ing; advances in those applications and more are described herein.
52 nnojirimycin and (+)-1-deoxyallonojirimycin, are described herein.
53 of an ester group followed by lactonization are described herein.
54 long with evidence of implementation success are described herein.
55 s and challenges of each of these approaches are described herein.
56 wo new oxo-molybdenum(V)-corrolato complexes are described herein.
57 f the clinical candidate, JNJ-42847922 (34), are described herein.
58 the last few years by the two new strategies are described herein.
59 interactions observed with the MDM2 protein are described herein.
60 iples derived from these theoretical studies are described herein.
61 nship studies that led to the discovery of 1 are described herein.
62 g protocols to test for these common alleles are described herein.
63 us sp. nov., and C. borealis sp. nov., which are described herein.
64 The design, synthesis, and evaluation of 2 are described herein.
65 dipity has played in the collaborations that are described herein.
66 rt, NaClO(3) crystals dyed with aniline blue are described herein.
67 shear or plasma turbidimetric assays, which are described herein.
68 ation of potent and selective PKD inhibitors are described herein.
69 n and synthesis of highly clustered antigens are described herein.
70 vivo properties of representative compounds are described herein.
71 The synthesis and reactivity of 1 are described herein.
72 of preliminary immunological investigations are described herein.
73 the identification of the clinical candidate are described herein.
74 The details of the synthesis are described herein.
75 ity of two thieno-separated purine analogues are described herein.
76 that of protein enzymes and larger ribozymes are described herein.
77 of unmodified DNA of any length or sequence are described herein.
78 steatohepatitis (NASH) with liver fibrosis, are described herein.
79 elated heteroarenes, and a scale-up reaction are described herein.
80 Education and Career Development Committee, are described herein.
81 that were evaluated as GSK-3beta inhibitors are described herein.
83 athways activated by these injurious stimuli are described herein and will serve as a basis for futur
84 accharides with distinct structural patterns is described herein, and the influence of the targeted s
85 phosphothionate (PT) analogues of PtdIns(5)P is described herein, and the resulting metabolically sta
86 e potent, selective 5-HT2C receptor agonists is described herein as we continue our efforts to optimi
88 dary aliphatic or aromatic and heterocyclic, is described herein by the reaction of easily prepared o
89 their photodynamic behavior within the cells are described herein, emphasizing their structure-activi
90 synthesis of these marine sponge metabolites is described herein, featuring an oxidative rearrangemen
91 f vitamin D using affinity based biosensors, are described herein; firstly, an immunosensor based on
93 ubsp. pruinosa (Vogel) Fortunato & Wunderlin is described herein for the first time, accounting for e
95 ics of Critical Illness and Injury Symposium are described herein, in addition to deliverables for th
96 f saturated nitrogen-containing heterocycles is described herein, involving the implementation of rut
97 graphene directly from a graphite electrode is described herein obviating the need for defect induci
99 e delimited, including four novel taxa which are described herein: T. botryosum, T. caeruloviride, T.
100 ations in the Drosophila Rap1 and Ras1 genes are described herein that interact genetically with fat
104 )-H bonds adjacent to benzazoles and ketones is described herein using DMF as a C-1 unit and TMSCN as